The E6 and E7 oncoprotein of human papillomavirus (HPV) is an ideal target for developing immunotherapeutic strategies against HPV-associated tumors. In this study, we reported that the recombinant lipoprotein containing inactive E6 (E6m) and E7 (E7m) biologically linking with bacterial lipid moiety (rlipo-E6mE7m), which could activate the maturation of mouse dendritic cells through toll-like receptor 2 (TLR2), skew the immune responses toward the Th1, and induce the E6- and E7-specific CTL responses. We further studied the efficacy of rlipo-E6mE7m in animal model. Mice immunized inoculated with TC-1 cancer cells and single dose immunization with rlipo-E6mE7m at day 7. The tumor size of those mice treated with rlipo-E6mE7m was reduced but not non-lipidated recombinant E6mE7m (rE6mE7m). These results demonstrated that the therapeutic effects of rlipo-E6E7m were dramatically increased because of the presence of TLR2 ligand that stimulated the innate immunity and CTL responses.